Cellosaurus logo
expasy logo

Cellosaurus OVCA433 (CVCL_0475)

[Text version]
Cell line name OVCA433
Synonyms OvCa433; OVCA 433; OvCa 433; OVCA-433; OVCA433_Bast; OVCAR-433; OVCAR 433; OVCAR433; SKOV-433; SK-OV-433; OV433
Accession CVCL_0475
Resource Identification Initiative To cite this cell line use: OVCA433 (RRID:CVCL_0475)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: 102.24 hours (GrayJW panel).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Exosome proteome analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
HLA typing Source: PubMed=26589293
Class I
HLA-AA*01:01,26:01
HLA-BB*15:17,39:01
HLA-CC*07:01,12:03
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.31
Native American1.3
East Asian, North0.31
East Asian, South0
South Asian0
European, North59.83
European, South38.24
Disease Ovarian serous adenocarcinoma (NCIt: C7550)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_DA01 (OVCA433/T40)CVCL_DA00 (OVCA433/TxT50)
Originate from same individual CVCL_IQ32 ! LAZ-444
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; PubMed=22710073; PubMed=25877200

Markers:
AmelogeninX
CSF1PO12,13
D2S133819,20
D3S135815,16
D5S81811,12
D7S82011,12
D8S117914,15
D13S3177,12
D16S53912
D18S5114
D19S43313
D21S1130
FGA24
Penta D13,14
Penta E7,12
TH019
TPOX9,11
vWA16,18

Run an STR similarity search on this cell line
Web pages http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=OVCA433_Bast
Publications

PubMed=7028788; DOI=10.1172/JCI110380
Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., Knapp R.C.
Reactivity of a monoclonal antibody with human ovarian carcinoma.
J. Clin. Invest. 68:1331-1337(1981)

PubMed=6346879; DOI=10.1016/0002-9378(83)90999-7
Berkowitz R.S., Kabawat S., Lazarus H., Colvin R.B., Knapp R.C., Bast R.C. Jr.
Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line.
Am. J. Obstet. Gynecol. 146:607-612(1983)

PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9
Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P., Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.
Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta.
Am. J. Obstet. Gynecol. 166:676-684(1992)

PubMed=10318951; DOI=10.1073/pnas.96.10.5722
Lau K.-M., Mok S.C., Ho S.-M.
Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells.
Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H
Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.
Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.
Mol. Carcinog. 28:236-246(2000)

PubMed=11793438; DOI=10.1002/gcc.1221
Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.
Multicolor spectral karyotyping of serous ovarian adenocarcinoma.
Genes Chromosomes Cancer 33:123-132(2002)

PubMed=16382445; DOI=10.1002/gcc.20300
Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K., Chen X., Sikic B.I.
Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines.
Genes Chromosomes Cancer 45:365-374(2006)

PubMed=19926575; DOI=10.1309/AJCPTK87EMMIKPFS
DeRycke M.S., Andersen J.D., Harrington K.M., Pambuccian S.E., Kalloger S.E., Boylan K.L.M., Argenta P.A., Skubitz A.P.N.
S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival.
Am. J. Clin. Pathol. 132:846-856(2009)

PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170
Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D., Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B., Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A., Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.
Genomic complexity and AKT dependence in serous ovarian cancer.
Cancer Discov. 2:56-67(2012)

PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224
Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J.
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Cancer Discov. 2:172-189(2012)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=24434149; DOI=10.1016/j.bbrc.2013.12.070
Sinha A., Ignatchenko V., Ignatchenko A., Mejia-Guerrero S., Kislinger T.
In-depth proteomic analyses of ovarian cancer cell line exosomes reveals differential enrichment of functional categories compared to the NCI 60 proteome.
Biochem. Biophys. Res. Commun. 445:694-701(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27561551; DOI=10.1038/ncomms12645
Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y., Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status.
Nat. Commun. 7:12645.1-12645.14(2016)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P.M., Novak M., Doodnauth S.A., Suarez Saiz F.J., Cullis J., Al-awar R., Neel B.G., McPherson J., Drapkin R.I., Ailles L., Mes-Masson A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resources MCCL; MCC:0000373
cancercelllines; CVCL_0475
Cell_Model_Passport; SIDM00966
Cosmic-CLP; 1480367
DepMap; ACH-002182
Anatomy/cell type resources BTO; BTO:0002566
Biological sample resources BioSample; SAMN03473291
Chemistry resources GDSC; 1480367
PharmacoDB; OVCA433_1216_2019
Encyclopedic resources Wikidata; Q54936989
Experimental variables resources EFO; EFO_0006723
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSM95433
GEO; GSM711706
GEO; GSM851931
GEO; GSM1670316
GEO; GSM2474992
Polymorphism and mutation databases Cosmic; 924148
Cosmic; 927568
Cosmic; 1175882
Cosmic; 1524355
Cosmic; 1709258
Progenetix; CVCL_0475
Proteomic databases PRIDE; PXD003668
PRIDE; PXD030304
Sequence databases EGA; EGAS00001000610
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number33